These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1442827)

  • 21. Biologicals: new horizons in pharmaceutical development.
    Oldham RK
    J Biol Response Mod; 1983; 2(3):199-206. PubMed ID: 6358418
    [No Abstract]   [Full Text] [Related]  

  • 22. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted therapies: cui prodest?
    Ferrari D; Foa P
    J Clin Oncol; 2007 Oct; 25(29):4691-2; author reply 4692. PubMed ID: 17925568
    [No Abstract]   [Full Text] [Related]  

  • 24. FDA clarifies rules, allows combining antiretrovirals in clinical trials. Food and Drug Administration.
    AIDS Treat News; 1999 Nov; (No 331):5-6. PubMed ID: 11367127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA and EMEA pool scientific advice.
    Katsnelson A
    Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharma consolidates its grip on post-antibody landscape.
    Sheridan C
    Nat Biotechnol; 2007 Apr; 25(4):365-6. PubMed ID: 17420728
    [No Abstract]   [Full Text] [Related]  

  • 27. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vision and will: the future of the FDA.
    Epstein D
    Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098
    [No Abstract]   [Full Text] [Related]  

  • 29. Growing pains for biopharmaceuticals.
    Ashton G
    Nat Biotechnol; 2001 Apr; 19(4):307-11. PubMed ID: 11283578
    [No Abstract]   [Full Text] [Related]  

  • 30. A piece of history.
    Nat Biotechnol; 2003 Aug; 21(8):831. PubMed ID: 12894179
    [No Abstract]   [Full Text] [Related]  

  • 31. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 32. Orphan products: definition and activities.
    Finkel MJ
    Prog Clin Biol Res; 1983; 127():159-71. PubMed ID: 6351098
    [No Abstract]   [Full Text] [Related]  

  • 33. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conflicts of interest in data monitoring of industry versus publicly financed clinical trials.
    Lachin JM
    Stat Med; 2004 May; 23(10):1519-21. PubMed ID: 15122730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maine law requires drug companies to provide clinical trial data.
    Appell D
    J Natl Cancer Inst; 2005 Sep; 97(17):1246. PubMed ID: 16145043
    [No Abstract]   [Full Text] [Related]  

  • 36. Bias in the design, interpretation, and publication of industry-sponsored clinical research.
    Hammerschmidt D
    Minn Med; 2008 Jun; 91(6):46-7. PubMed ID: 18616022
    [No Abstract]   [Full Text] [Related]  

  • 37. Newer monoclonal antibodies for hematological malignancies.
    Castillo J; Winer E; Quesenberry P
    Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FDA perspective on specifications for biotechnology products--from IND to PLA.
    Murano G
    Dev Biol Stand; 1997; 91():3-13. PubMed ID: 9413677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA and pharma seek better ways to assess drug safety, efficacy in clinical trials.
    Mitka M
    JAMA; 2012 Jun; 307(24):2576-7. PubMed ID: 22735406
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.